Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease

Liver International

Volumn 29, Issue 9, 2009, Pages 1389-1395

  Waanders, Esmé ^a   van Keimpema, Loes ^a   Brouwer, Johannes T ^b   van Oijen, Martijn G H ^a   Aerts, Raymond ^c   Sweep, Fred C G J ^a   Nevens, Frederik ^c   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CA19 9; Hepatic cyst fluid; Immunohistochemistry; Polycystic liver Disease; Serum

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FENESTRATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CYST; LIVER POLYCYSTIC DISEASE; LIVER TRANSPLANTATION; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; SURGICAL DRAINAGE; TUMOR VOLUME; AGED; BLOOD; CHEMISTRY; CYST; CYST FLUID; FOLLOW UP; LIVER DISEASE; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; CA-19-9 ANTIGEN; CYST FLUID; CYSTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER DISEASES; MALE; MIDDLE AGED;

EID: 70449711389     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02055.x     Document Type: Article

References (31)

1. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983; 43: 5489-92.
2. Arakawa Y, Ariga H, Kano M, et al. Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers. Jpn J Med 1985; 24: 121-30.
3. Goonetilleke KS, Siriwardena A.K. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33: 266-70.
4. Jalanko H, Kuusela P, Roberts P, et al. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37: 218-22.
5. Kokocinska D, Jarzab B, Krol R, et al. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers. J Environ Pathol Toxicol Oncol 1996; 15: 283-7.
6. Ito S, Gejyo F. Elevation of serum CA19-9 levels in benign diseases. Intern Med 1999; 38: 840-1.
7. Maestranzi S, Przemioslo R, Mitchell H, Sherwood R.A. The effect of benign and malignant liver disease on the tumour markers CA19-9 and C.E.A. Ann Clin Biochem 1998; 35(Part 1): 99-103.
8. Murray MD, Burton FR, Di Bisceglie A.M. Markedly elevated serum CA 19-9 levels in association with a benign biliary stricture due to primary sclerosing cholangitis. J Clin Gastroenterol 2007; 41: 115-7.
9. Atkinson BF, Ernst CS, Herlyn M, et al. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res 1982; 42: 4820-3.
10. Qian Q, Li A, King BF, et al. Clinical profile of autosomal dominant polycystic liver disease. Hepatology 2003; 37: 164-71.
11. Lazaridis KN, Strazzabosco M, Larusso N.F. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004; 127: 1565-77.
12. Cheung J, Scudamore CH, Yoshida E.M. Management of polycystic liver disease. Can J Gastroenterol 2004; 18: 666-70.
13. Melnick P.J. Polycystic liver; analysis of seventy cases. AMA Arch Pathol 1955; 59: 162-72.
14. Drenth JP, Te Morsche RH, Smink R, Bonifacino JS, Jansen J.B. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat Genet 2003; 33: 345-7.
15. Drenth JP, Martina JA, Te Morsche RH, Jansen JB, Bonifacino J.S. Molecular characterization of hepatocystin, the protein that is defective in autosomal dominant polycystic liver disease. Gastroenterology 2004; 126: 1819-27.
16. Pirenne J, Aerts R, Yoong K, et al. Liver transplantation for polycystic liver disease. Liver Transpl 2001; 7: 238-45.
17. van Keimpema L., Ruurda JP, Ernst MF, van Geffen HJ, Drenth J.P. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg 2008; 12: 477-82.
18. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994; 343: 824-7.
19. Waanders E, Croes HJ, Maass CN, et al. Cysts of PRKCSH mutated polycystic liver disease patients lack hepatocystin but express Sec63p. Histochem Cell Biol 2008; 129: 301-10.
20. Gabow PA, Johnson AM, KaehnyWD, et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology 1990; 11: 1033-7.
21. Howaizi M, Abboura M, Krespine C, et al. A new cause for CA19.9 elevation: heavy tea consumption. Gut 2003; 52: 913-4.
22. Strom BL, Iliopoulos D, Atkinson B, et al. Pathophysiology of tumor progression in human gallbladder: flow cytometry, CEA, and CA 19-9 levels in bile and serum in different stages of gallbladder disease. J Natl Cancer Inst 1989; 81: 1575-80.
23. Roitbak T, Ward CJ, Harris PC, et al. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol Biol Cell 2004; 15: 1334-46.
24. Russo RJ, Husson H, Joly D, et al. Impaired formation of desmosomal junctions in ADPKD epithelia. Histochem Cell Biol 2005; 124: 487-97.
25. Silberberg M, Charron AJ, Bacallao R, Wandinger-Ness A. Mispolarization of desmosomal proteins and altered intercellular adhesion in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2005; 288: F1153-63.
26. Waanders E, van Krieken JH, Lameris AL, Drenth J.P. Disrupted cell adhesion but not proliferation mediates cyst formation in polycystic liver disease. Mod Pathol 2008; 21: 1293-302.
27. Ritter von C, Eder MI, Stieber P, et al. Biliary mucin secreted by cultured human gallbladder epithelial cells carries the epitope of CA 19-9. Anticancer Res 1997; 17: 2931-4.
28. Waanders E, Lameris AL, Op den Camp HJ, et al. Hepatocystin is not secreted in cyst fluid of hepatocystin mutant polycystic liver patients. J Proteome Res 2008; 7: 2490-5.
29. Yanai H, Tada N. A simple hepatic cyst with elevated serum and cyst fluid CA19-9 levels: a case report. J Med Case Reports 2008; 2: 329.
30. Yuksel BC, Yildiz Y, Ozturk B, et al. Serum tumor marker CA19-9 in the follow-up of patients with cystic echinococcosis. Am J Surg 2008; 195: 452-6.
31. Magnani J.L. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys 2004; 426: 122-31.